{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042663","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.866466+00:00","generated_at":"2026-05-21T19:11:43.785205+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"TherapeuticsMD Q1 net loss narrows to $636K; license revenue up 26%","bullets":["Net loss from continuing ops $(636)K ($0.06/sh) vs $(809)K ($0.07/sh) in Q1 2024.","License revenue $393K, up 25.8% from $313K, driven by Mayne License sales changes.","Operating expenses $1,264K, down 13.1% from prior year on royalty business efficiencies.","Cash and equivalents $5.7M at March 31, 2025; no debt disclosed.","Company continues evaluating strategic alternatives including M&A or asset sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042663","json":"https://secwatch.observer/filing/0001213900-25-042663.json","markdown":"https://secwatch.observer/filing/0001213900-25-042663.md","text":"https://secwatch.observer/filing/0001213900-25-042663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390025042663/0001213900-25-042663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390025042663/ea0241986-8k_therap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T19:11:43.785205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}